arsenic trioxide has been researched along with Ph 1 Chromosome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Q | 1 |
| Brüggenolte, N; Güller, S; Hoelzer, D; Orleth, A; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
2 other study(ies) available for arsenic trioxide and Ph 1 Chromosome
| Article | Year |
|---|---|
Chronic myelogenous leukemia in accelerated phase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic | 2005 |
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cells, Cultured; Colony-Forming Units Assay; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Philadelphia Chromosome; Proto-Oncogene Proteins c-abl; Tumor Cells, Cultured; U937 Cells | 2000 |